Neuroprotection: Extrapolating from Neurologic Diseases to the Eye

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages

  Danesh Meyer, Helen V ^a   Levin, Leonard A ^b,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; DISUFENTON SODIUM; DIZOCILPINE; MEMANTINE; METHYLPREDNISOLONE; NALOXONE; NEUROPROTECTIVE AGENT; PLACEBO; TCH 346; TIMOLOL; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; BRAIN INFARCTION SIZE; CHRONOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EYE DISEASE; GLAUCOMA; HUMAN; ISCHEMIC OPTIC NEUROPATHY; LEBER HEREDITARY OPTIC NEUROPATHY; LOW DRUG DOSE; MEDICATION ERROR; METHODOLOGY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA INJURY; SCANNING LASER OPHTHALMOSCOPY; SPINAL CORD; STROKE; TREATMENT OUTCOME; VISION; VISUAL IMPAIRMENT;

EID: 67650432133     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.03.029     Document Type: Article

References (44)

1. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330 (1994) 585-591
2. Lacomblez L., Bensimon G., Leigh P.N., et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 47 (1996) S242-S250
3. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
4. Allergan Inc. Press Releases on Memantine Trials. http://www.allergan.com/newsroom/index.htm Accessed: November 15, 2008
5. Hare W.A., WoldeMussie E., Lai R.K., et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey: I. Functional measures. Invest Ophthalmol Vis Sci 45 (2004) 2625-2639
6. Hare W.A., WoldeMussie E., Weinreb R.N., et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey: II. Structural measures. Invest Ophthalmol Vis Sci 45 (2004) 2640-2651
7. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 33 (2002) 306-307
8. Cheng Y.D., Al-Khoury L., and Zivin J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1 (2004) 36-45
9. Faden A.I. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr Opin Neurol 15 (2002) 707-712
10. Newman N.J., Biousse V., David R., et al. Prophylaxis for second eye involvement in Leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol 140 (2005) 407-415
11. BRAION study group, Wilhelm B., Ludtke H., and Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 244 (2006) 551-558
12. Krupin T., Liebmann J.M., Greenfield D.S., Rosenberg L.F., Ritch R., and Yang J.W. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 112 (2005) 376-385
13. Evans D.W., Hosking S.L., Gherghel D., and Bartlett J.D. Contrast sensitivity improves after brimonidine therapy in primary open-angle glaucoma: a case for neuroprotection. Br J Ophthalmol 87 (2003) 1463-1465
14. Aung T., Oen F.T., Wong H.T., et al. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Br J Ophthalmol 88 (2004) 88-94
15. Lees K.R. Advances in neuroprotection trials. Eur Neurol 45 (2001) 6-10
16. Alonso de Lecinana M., Diez-Tejedor E., Carceller F., and Roda J.M. Cerebral ischemia: from animal studies to clinical practice. Should the methods be reviewed?. Cerebrovasc Dis 11 (2001) 20-30
17. Tolias C.M., and Bullock M.R. Critical appraisal of neuroprotection trials in head injury: what have we learned?. NeuroRx 1 (2004) 71-79
18. Roof R.L., and Hall E.D. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 17 (2000) 367-388
19. Fox G.B., LeVasseur R.A., and Faden A.I. Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: implications for gene targeting approaches to neurotrauma. J Neurotrauma 16 (1999) 377-389
20. Levin L.A., and Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care 14 (2008) S11-S14
21. Savitz S.I., and Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61 (2007) 396-402
22. Bracken M.B., and Holford T.R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 79 (1993) 500-507
23. O'Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., van der Worp B.H., and Howells D.W. 1,026 experimental treatments in acute stroke. Ann Neurol 59 (2006) 467-477
24. Faden A.I., Jacobs T.P., Smith M.T., and Zivin J.A. Naloxone in experimental spinal cord ischemia: dose-response studies. Eur J Pharmacol 103 (1984) 115-120
25. Olanow C.W., Schapira A.H., LeWitt P.A., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
26. Wahlgren N.G., and Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies-the need for new approaches. Cerebrovasc Dis 17 (2004) 153-166
27. Levin L.A. Extrapolation of animal models of optic nerve injury to clinical trial design. J Glaucoma 13 (2004) 1-5
28. Grotta J.C. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside. The Feinberg Lecture. Stroke 30 (1999) 1722-1728
29. Waldmeier P., Bozyczko-Coyne D., Williams M., and Vaught J.L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72 (2006) 1197-1206
30. Bebarta V., Luyten D., and Heard K. Emergency medicine animal research: does use of randomization and blinding affect the results?. Acad Emerg Med 10 (2003) 684-687
31. Takeshima R., Kirsch J.R., Koehler R.C., and Traystman R.J. Tirilazad treatment does not decrease early brain injury after transient focal ischemia in cats. Stroke 25 (1994) 670-676
32. Hellstrom H.O., Wanhainen A., Valtysson J., Persson L., and Hillered L. Effect of tirilazad mesylate given after permanent middle cerebral artery occlusion in rat. Acta Neurochir (Wien) 129 (1994) 188-192
33. Savitz S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 205 (2007) 20-25
34. Drummond J.C., Piyash P.M., and Kimbro J.R. Neuroprotection failure in stroke. Lancet 356 (2000) 1032-1033
35. Corbett D., and Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. Prog Neurobiol 54 (1998) 531-548
36. Bordi F., Pietra C., Ziviani L., and Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol 145 (1997) 425-433
37. Yenari M.A., Kunis D., Sun G.H., et al. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 153 (1998) 223-233
38. Valtysson J., Hillered L., Andine P., Hagberg H., and Persson L. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. Acta Neurochir (Wien) 129 (1994) 58-63
39. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
40. Gladstone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
41. Duncan P.W., Jorgensen H.S., and Wade D.T. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 31 (2000) 1429-1438
42. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32 (2001) 1598-1606
43. Fisher M., Hanley D.F., Howard G., Jauch E.C., and Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 38 (2007) 245-248
44. Csaky K.G., Richman E.A., and Ferris III F.L. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 49 (2008) 479-489